BioNano Genomics (BNGO) Announces Earnings Results, Misses Estimates By $0.14 EPS

BioNano Genomics (NASDAQ:BNGO) issued its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.14), Morningstar.com reports.

Shares of BioNano Genomics stock opened at $4.20 on Friday. BioNano Genomics has a 52-week low of $3.50 and a 52-week high of $10.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.19 and a quick ratio of 4.72.

Several institutional investors have recently modified their holdings of BNGO. Monashee Investment Management LLC acquired a new position in shares of BioNano Genomics during the third quarter worth about $1,300,000. Sio Capital Management LLC acquired a new position in BioNano Genomics during the third quarter worth about $7,353,000. Federated Investors Inc. PA acquired a new position in BioNano Genomics during the third quarter worth about $56,704,000. Worth Venture Partners LLC grew its position in BioNano Genomics by 1,666.6% during the fourth quarter. Worth Venture Partners LLC now owns 79,902 shares of the company’s stock worth $417,000 after buying an additional 75,379 shares during the period. Finally, Millennium Management LLC acquired a new position in BioNano Genomics during the fourth quarter worth about $254,000. Institutional investors and hedge funds own 11.50% of the company’s stock.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research cut shares of BioNano Genomics from a “hold” rating to a “sell” rating in a research report on Monday, December 31st. Roth Capital reissued a “buy” rating on shares of BioNano Genomics in a research report on Tuesday, February 5th. Maxim Group raised shares of BioNano Genomics to a “buy” rating and set a $11.00 price target for the company in a research report on Wednesday, March 6th. Finally, ValuEngine cut shares of BioNano Genomics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st.

COPYRIGHT VIOLATION NOTICE: This report was published by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.wkrb13.com/2019/03/15/bionano-genomics-bngo-announces-earnings-results.html.

BioNano Genomics Company Profile

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Recommended Story: Net Income

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.